The fecal immunochemical test (fit): Selected aspects regarding its effectiveness for colorectal cancer screening in Quebec City

Caron, Mireille; Lamarre, Gabriel; Grégoire, Philippe; Simonyan, David; Laflamme, Nathalie

doi:10.1016/j.pmedr.2018.08.003

Cited by 4 publications

(2 citation statements)

References 34 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30 While FIT is considered to have more clinical and analytical sensitivity over other tests in detecting occult blood, a marker for neoplasms, 31 how the prioritization of FIT patients impacted other colonoscopy-seeking patients has not been explored. FIT positive patients in Quebec may constitute a higher risk population than participants in other screening programs, 32 as the province has the highest positivity threshold across Canada (175ng/mL), 33 which may support their prioritization. Our study suggests that with finite colonoscopy resources, wait times for other indicated conditions may have been displaced by this reorganization.…”

Section: Discussionmentioning

confidence: 99%

Impact of COVID-19 Pandemic on Colonoscopy Wait Times by Procedure Indication

Thibault,

Barkun,

Martel

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Patients are referred for colonoscopy for symptom assessment, screening, and surveillance. Public health measures to mitigate the spread of the COVID−19 pandemic disrupted services and increased patient delays for colonoscopy services in Quebec. The differential impact of these interruptions by colonoscopy indication is largely unknown. Methods: Using 2018−2022 retrospective clinical data from two high-volume Montreal endoscopy centres and provincial administrative data, we characterized changes in colonoscopy wait times and the proportion of waitlisted patients who were delayed (wait time exceeded provincial guidelines) by procedure indication and demographics. We used regression to examine patient characteristics associated with delayed procedures during pre- and intra−COVID−19 periods. We used time series analysis to characterize trends in the proportion of waitlisted patients delayed. Results: The COVID-19−related public health measures resulted in record-high delays (median increase in wait times of 34−159% across indications). While older patients experienced longer wait times pre-pandemic, intra−COVID−19 wait times increased disproportionately for patients younger than 50. The proportion of waitlisted patients delayed peaked mid−2020 (56.9% for screening; 56.0% for symptom assessment patients). By early 2022, the proportion delayed had fallen to 37.3% for screening patients but remained at 53.8% for symptom assessment patients. Conclusions: In Quebec, intra-COVID-19 colonoscopy delays disproportionately impacted symptom assessment procedures and younger patients. Additional capacity or improved triaging may be needed to address persistent delays. Understanding the effects of the pandemic on colonoscopy services can help inform strategies to mitigate harms from on-going delays in Quebec.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of COVID-19 Pandemic on Colonoscopy Wait Times by Procedure Indication

Thibault,

Barkun,

Martel

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…To date, all approved immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed death ligand 1 (PD-L1). These molecules serve as key inhibitors of T-cell activation and function ( 1 , 2 ). Since ipilimumab was approved by the FDA for metastatic melanoma in 2011, various ICIs have been introduced, Numerous studies have demonstrated the benefits of ICIs in non-small cell lung cancer ( 3 , 4 ), liver cancer ( 5 ), triple-negative breast cancer ( 6 ), gastroesophageal cancer ( 7 ), ovarian cancer ( 8 ) and other malignant tumors.…”

Section: Introductionmentioning

confidence: 99%

Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis

Zou,

Song,

Yong

2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundImmune checkpoint inhibitors (ICIs) have been proven to be an effective treatment strategy for a variety of malignant tumors. However, only a subset of patients can benefit from ICIs due to factors such as drug resistance. Therefore, it is crucial to identify biomarkers that can accurately predict the efficacy of ICIs and provide a basis for individualized immunotherapy. In this study, we conducted a systematic review and meta-analysis to explore whether the chemokine interleukin 8 (IL-8) can be used as a biomarker to evaluate the efficacy of ICIs treatment.MethodsWe conducted a comprehensive search of several databases, including PubMed, Embase, Web of Science, and Cochrane, to identify relevant articles published up to June 08, 2023. Our inclusion criteria were limited to cohort studies and clinical trials that reported hazard ratios (HR) and 95% confidence intervals (CI) for overall survival (OS) and/or progression-free survival (PFS), as well as the objective response rate (ORR), in cancer patients with high and low IL-8 expression. For data analysis, we used Revman to generate forest plots, subgroup analysis, and assess publication bias. Additionally, Stata was utilized for sensitivity analysis and further examination of publication bias.ResultsA total of 24 datasets, involving 3190 participants, were selected from 14 studies. The meta-analysis revealed a reduction in ORR, OS, and/or PFS in the high IL-8 group after treatment with ICIs compared to the low IL-8 group.ConclusionIL-8 can serve as a biomarker for predicting the efficacy of ICIs. Patients with lower expression of IL-8 may benefit from ICIs treatment.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=383188, identifier CRD42022383188.

show abstract